The antisecretive effects of lanreotide on pancreatic beta-cells, which may result in reduced plasmatic insulin secretion and IGF1 production, could further contribute to the observed benefit of lanreotide in patients with DM [22,23]. The gene discussed is INS; the disease is diabetes mellitus.